Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
On November 16, 2026, Amesite
Inc. issued a press release announcing a new NurseMagic® enterprise agreement with a healthcare organization serving approximately
2,000 patients. A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report and is incorporated by reference
herein.
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Exhibit 99.1
Amesite Signs New 2,000-Patient NurseMagic®
Enterprise Customer, Extending Growth Among Large Healthcare Organizations
Amesite announces its latest major enterprise
win, increasing its revenue and deploying AI automations for another large healthcare organization in just days on its secure, AI-native
infrastructure.
DETROIT, November 16, 2026 (GLOBE NEWSWIRE)
-- Amesite Inc. (Nasdaq: AMST), an adaptive AI technology company and developer of the AI-native NurseMagic® documentation
platform and LynkMagic™ enterprise solutions, today announced a new NurseMagic® enterprise agreement with a healthcare
organization serving approximately 2,000 patients.
The contract ramps Amesite’s revenue, user
base and patient census, and demonstrates another large company win for the Company’s portfolio. This announcement follows other
substantial wins including a sales win under the minimum pricing model, a 2,700-census enterprise customer win in May 2026, a trading
partner agreement enabling secure connectivity with an established homecare technology platform in March 2026, and the launch of its
AI-native NurseMagic® EMR in December 2025. These milestones demonstrate continued execution of the Company's strategy
to expand NurseMagic® adoption among larger healthcare organizations.
Amesite combines AI-native engineering with enterprise-scale
execution, deploying sophisticated, production-ready AI systems in days rather than months. This capability enables Amesite to deliver
enterprise-scale solutions with exceptional speed and efficiency, supporting attractive, high-margin subscription economics for mid-sized
organizations while meeting the complex demands of large healthcare enterprises.
Dr. Ann Marie Sastry, Founder and CEO of Amesite,
said, “We demonstrate production-ready AI systems during enterprise sales discussions and deploy customer-specific capabilities
in days, not months. Our AI-native infrastructure enables us to meet complex healthcare requirements without lengthy development cycles
or replacement of customers' existing systems. We are now converting these engineering advantages into larger enterprise agreements and
recurring revenue opportunities.”
NurseMagic® automates work beyond
transcription, transforming patient encounters into structured documentation and completing customer-specific electronic medical record
(EMR) assessments, care plans, and forms. Its production capabilities include identifying missing information, generating targeted follow-up
questions, and populating existing EMR workflows. NurseMagic® Record adds secure ambient and mobile recording, including
offline capture with automatic synchronization when connectivity returns.
Together, these capabilities enable sophisticated
enterprise automation within existing healthcare infrastructure. No rip and replace.
Kalie Wortinger, Head of Engineering at Amesite,
said, “Our AI-native engineering infrastructure enables us to deliver increasingly sophisticated enterprise solutions at exceptional
speed. We now ship more than 13 times as much code each quarter as we did in the first quarter of 2025, with another 37% increase in the
third quarter of 2026 over the second quarter, all without adding engineers. By building customer-specific capabilities on our existing
secure, HIPAA-aligned infrastructure, we can bring new products into production in days and deliver new features in hours, allowing us
to serve increasingly complex healthcare enterprises efficiently and at scale.”
Sai K. Nittala, Head of AI at Amesite, said,
“Large healthcare organizations have established technology stacks, but many of the documentation tasks within those systems
remain entrenched, tedious, and expensive to perform. Our agility allows us to fill those gaps quickly with AI capabilities tailored to
different care settings and operational requirements. We deliver complex customer-specific solutions and sit on top of existing systems.
This enables us to build value and ramp sales with large enterprises, without rebuilding our core platform.”
Madison Bush, Director of Corporate Operations
at Amesite, said, "Our marketing results are measurable: median customer census at signing has increased 4x from 2025 to 2026,
demonstrating our progress in attracting larger organizations and converting market intelligence into enterprise sales.”
Amesite has methodically expanded its customer
base with increasingly large healthcare market segments, progressing from hospice and home care to skilled nursing, senior living, and
enterprise workflows serving Medicare and Medicaid populations. Each expansion has built on the Company's existing AI infrastructure,
positioning Amesite to serve increasingly complex organizations across the U.S. non-acute and post-acute healthcare markets.
This most recent contract win expands Amesite’s
customer portfolio into healthcare services for rural Medicare and Medicaid populations. Across the U.S., this segment comprises 64.5
million rural Americans, including 17.8 million Medicaid enrollees and 11.8 million Medicare beneficiaries. Based on projected 2026 spending
per enrollee, these populations represent an estimated $232.9 billion in annual Medicaid spending and
$224.0 billion in Medicare spending, respectively, totaling approximately $456.9 billion in combined
annual healthcare spending. Overall, segments represented by customers in Amesite's portfolio have a combined estimated U.S. market
size of approximately $1.5 trillion.
About Amesite Inc.
Amesite (NASDAQ: AMST) is an AI-driven company
with an immediate aim to transform the $1.5 trillion non-acute care segments. Its flagship product, NurseMagic®, streamlines
documentation for nurses and caregivers, reducing the time required from 20 minutes to just 20 seconds. NurseMagic® is
used by over 100 professions to improve care, enhance operational efficiency and improve financial performance.
Built on proprietary AI trained on industry-specific
data, NurseMagic® meets HIPAA regulations while improving accuracy and efficiency. The platform serves B2B and B2C users
across 50 states and 21 countries, offering seamless integration into healthcare workflows and translations to over 50 languages.
Forward-Looking Statement
This communication contains forward-looking statements
(including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act
of 1933, as amended) concerning the Company and its business.
Forward-looking statements generally include statements
that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,”
“should,” “would,” “expect,” “plan,” “believe,” “intend,” “look
forward,” and other similar expressions among others. Statements that are not historical facts are forward-looking statements.
Forward-looking statements are based on current
beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could
differ materially from those contained in any forward-looking statement. Risks facing the Company and its business are set forth in the
Company's filings with the SEC.
Except as required by applicable law, the Company
undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as
a result of new information, future events or otherwise.
Investor Relations
ir@amesite.com